ZimVie Reports Q2 2025 Financial Results with $116.7M in Net Sales

ZimVie Inc. reported its financial results for the second quarter of 2025, revealing net sales of $116.7 million, a slight decrease from $116.8 million in the same period of 2024. For the first half of 2025, the company generated $228.7 million in revenue, down from $235.0 million year-over-year. The decline in sales was attributed primarily to decreased sales of dental implant systems and biomaterial products, as well as the exit from a transition manufacturing agreement with its former parent company. Despite the revenue drop, ZimVie achieved an operating profit of $1.3 million for the quarter, a significant improvement from an operating loss of $6.7 million in the prior year.

The company’s cost of products sold (excluding intangible asset amortization) decreased to $41.4 million in the second quarter of 2025, compared to $43.5 million in the same quarter of 2024. This reduction was driven by manufacturing efficiencies and the aforementioned exit from the transition manufacturing agreement. ZimVie’s operating expenses also saw a decline, with selling, general, and administrative expenses falling to $59.6 million from $62.4 million year-over-year. The company reported a net loss from continuing operations of $3.9 million for the quarter, an improvement from a loss of $4.0 million in the same period last year.

In terms of strategic developments, ZimVie completed the sale of its spine segment in April 2024 for $377 million, which has been classified as discontinued operations in its financial statements. The company also made a small acquisition in April 2025, purchasing the dental business of a distributor in Costa Rica for $3.3 million. This acquisition is expected to enhance ZimVie’s market presence in the region. As of June 30, 2025, ZimVie reported total assets of $758.2 million, with cash and cash equivalents amounting to $70.2 million.

Operationally, ZimVie has focused on optimizing its workforce and reducing costs, resulting in a decrease in research and development expenses to $5.7 million for the second quarter, down from $6.6 million in the prior year. The company’s employee headcount has also been adjusted in line with its restructuring initiatives. ZimVie continues to monitor market conditions closely, particularly in light of recent tariff changes that could impact its supply chain and cost structure.

Looking ahead, ZimVie has entered into a merger agreement with Zamboni Parent Inc., which will acquire the company for $19.00 per share, representing a significant premium over its recent trading price. This merger is subject to stockholder approval and customary closing conditions. The company believes that its current cash reserves, along with cash flows from operations, will be sufficient to meet its liquidity needs for the foreseeable future, as it navigates through this transitional phase.